AndzonBio2 and Cambridge Partner on Neuroinflammation Therapies
PARIS and CAMBRIDGE, UK, May 13, 2026 AndzonBio2 announced a strategic collaboration with the ALBORADA Drug Discovery Institute (ADDI)...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
PARIS and CAMBRIDGE, UK, May 13, 2026 AndzonBio2 announced a strategic collaboration with the ALBORADA Drug Discovery Institute (ADDI)...
